Pyridylmethylthio derivatives as VEGF inhibitors. Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 24, 2010, Pages 7234-7238

  Tajima, Hisashi ^a,b   Honda, Takahiro ^a,b   Kawashima, Kenji ^a   Sasabuchi, Yoshimasa ^a   Yamamoto, Minoru ^a,b   Ban, Masakazu ^a,b   Okamoto, Kazuyoshi ^a   Inoue, Kenji ^a   Inaba, Takaaki ^a   Takeno, Yuriko ^a   Aono, Hiroyuki ^a,b  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

AMD; Cancer; Pyridylmethylthio; RA; VEGF

Indexed keywords

PYRIDINE DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; DRUG EFFICACY; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION; SUBRETINAL NEOVASCULARIZATION; TUMOR XENOGRAFT;

ANILIDES; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL LINE; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; MICE; NEOPLASMS; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78449303072     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.10.096     Document Type: Article

References (19)

1. M. Shibuya Folia Pharmacol. Japonica 122 6 2003 498
2. H. Sone, Y. Kawakami, M. Sakauchi, Y. Nakamura, A. Takahashi, H. Shimano, Y. Okuda, T. Segawa, H. Suzuki, and N. Yamada Biochem. Biophys. Res. Commun. 281 2001 562
3. A. Kvanta, P.V. Algvere, L. Berglin, and S. Seregard Invest. Ophthalmol. Vis. Sci. 37 1996 1929
4. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Nat. Rev. Drug Disc. 3 2004 391
5. L. Sun, C. Liang, S. Shirazian, Y. Zhou, T. Miller, J. Cui, J.Y. Fukuda, J.Y. Chu, A. Sistla, T.C. Luu, F. Tang, J. Wei, and C. Tang J. Med. Chem. 46 2003 1116
6. L.F. Hennequin, E.S.E. Stokes, A.P. Thomas, C. Johnstone, P.A. Ple, D.J. Ogilvie, M. Dukes, S.R. Wedge, J. Kendrew, and J.O. Curwen J. Med. Chem. 45 2002 1300
7. K. Kubo, T. Shimizu, S. Ohyama, H. Murooka, A. Iwai, K. Nakamura, K. Hasegawa, Y. Kobayashi, N. Takahashi, K. Takahashi, S. Kato, T. Izawa, and T. Isoe J. Med. Chem. 48 2005 1359
8. G. Bold, K.H. Altmann, F. Jorg, M. Lang, P.W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, E. Buchdunger, R. Cozens, S. Ferrari, P. Furet, F. Hofmann, G. Martiny-Baron, J. Mestan, J. Rosel, M. Sills, D. Stover, E. Masso, R. Roth, C. Schlachter, W. Vetterli, D. Wyss, and J. Wood J. Med. Chem. 43 2000 2310
9. G. Bold, K.H. Altmann, F. Jorg, M. Lang, P.W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, E. Buchdunger, R. Cozens, S. Ferrari, F. Pascal, F. Hofmann, G. Martiny-Baron, J. Mestan, J. Rosel, M. Sills, D. Stover, E. Masso, R. Roth, C. Schlachter, W. Vetterli, D. Wyss, and J. Wood J. Med. Chem. 43 2000 3200
10. P.W. Manley, P. Furet, G. Bold, J. Brueggen, J. Mestan, T. Meyer, C.R. Schnell, and J. Wood J. Med. Chem. 45 2002 5687
11. A. Polverino, A. Coxon, C. Starnes, Z. Diaz, T. DeMelfi, L. Wang, J. Bready, J. Estrada, R. Cattley, S. Kaufman, D. Chen, Y. Gan, G. Kumar, J. Meyer, S. Neervannan, G. Alva, J. Talvenheimo, S. Montestruque, A. Tasker, V. Patel, R. Radinsky, and R. Kendall Cancer Res. 66 2006 8715
12. P.M. Manley, G. Bold, J. Brüggen, G. Fendrich, P. Furet, J. Mestan, C. Schnell, B. Stolz, T. Meyer, B. Meyhack, W. Stark, A. Strauss, and J. Wood Biochim. Biophys. Acta, Proteins Proteomics 1697 2004 17
13. T. Honda, H. Tajima, Y. Kaneko, M. Ban, T. Inaba, Y. Takeno, K. Okamoto, and H. Aono Bioorg. Med. Chem. Lett. 18 2008 2939
14. T. Annie, T. Fong, L.K. Shawver, L. Sun, C. Tang, H. App, T.J. Powell, Y.H. Kim, R. Schreck, X. Wang, W. Risau, A. Ullrich, K.P. Hirth, and G. McMahon Cancer Res. 59 1999 99
15. HUVEC was cultured into collagen coated well plate. After one day incubation VEGF and a test compound were added. After three days incubation, cell number was counted. Compared with control, cell growth rate was calculated; see also Supplementary data.
16. L.Z. Carpino J. Am. Chem. Soc. 115 1993 4397
17. (a) Prewett, M.; Huber, J.; Li, Y.; Santiago, A.; O'Connor, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D. J. Cancer Res. 1999, 59, 5209; (b) B16 cell suspension was s.c. injected into the C57BL/6 mouse (female, six weeks old) under anesthesia. The suspension of a test compound was administrated orally once a day every day. Ten days after injection, the weight of extirpated tumor tissue was measured. Compared with control, anti-cancer effect was calculated; see also Supplementary data.
18. The adjuvant was injected subcutaneously into a left hind paw sole of Lewis rats (male, nine weeks old) to induce arthritis. The suspension of a test compound was administrated orally once a day every day. Twenty one days after induction, the paw volume was measured. Compare with control, paw edema inhibition rate was calculated; see also Supplementary data.
19. (a) Xianjin, X.; Ogata, N.; Komada, M.; Yamamoto, C.; Takahashi, K.; Omori, K.; Uyama, M. Graefe's Arch. Clin. Exp. Ophthalmol. 1997, 235, 313; (b) Under anesthesia and mydriasis, photocoagulation was performed in a Bruch's membrane of Brown Norway rats (male, eight weeks old) with a krypton laser. The suspension of a test compound was administrated orally once a day every day. Seven days after photocoagulation, fluorescein solution was injected into a tail vein. After fluorescein fundus photography was performed, fluorescence leak was counted. Compared with control, Neovascularization incidence rate was calculated; see also Supplementary data.